Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

South Korea's pilot sickness benefit program, launched in 2022 across six regions and currently operating in 14 regions as of 2025, represents a critical juncture in the country's social protection development. While ostensibly designed with inclusive eligibility criteria, the program reveals fundamental paradoxes that illuminate deeper structural inequalities within Korea's dualized labor market. This opinion piece examines how current design choices risk undermining universal health coverage goals by systematically excluding the most precarious workers. The program's design features-including low replacement rates (60% of the minimum wage) and extended waiting periods-created perverse incentives where the most vulnerable workers accepted the least favorable conditions. This pattern exemplifies what Korpi and Palme termed the "paradox of redistribution," where targeted approaches ultimately prove less effective than universal ones, with the second phase's restriction to the bottom 50% income bracket threatening to exacerbate this paradox. Successful implementation will depend on integrating equity, people-centered design, and gender-transformative perspectives into every phase-design, operation, evaluation, and reform. In doing so, South Korea has the opportunity to offer a model of sickness protection that does not simply patch gaps, but actively reshapes the structures that produce health and economic inequalities in the first place.

Download full-text PDF

Source
http://dx.doi.org/10.35371/aoem.2025.37.e25DOI Listing

Publication Analysis

Top Keywords

sickness benefit
8
benefit leaving
4
leaving south
4
south korea's
4
korea's pilot
4
pilot sickness
4
benefit program
4
program launched
4
launched 2022
4
2022 regions
4

Similar Publications

South Korea's pilot sickness benefit program, launched in 2022 across six regions and currently operating in 14 regions as of 2025, represents a critical juncture in the country's social protection development. While ostensibly designed with inclusive eligibility criteria, the program reveals fundamental paradoxes that illuminate deeper structural inequalities within Korea's dualized labor market. This opinion piece examines how current design choices risk undermining universal health coverage goals by systematically excluding the most precarious workers.

View Article and Find Full Text PDF

Introducing statutory paid sick leave in South Korea: necessity and key considerations.

Ann Occup Environ Med

September 2025

Center for Occupational and Environmental Medicine, Hanil General Hospital, Seoul, Korea.

South Korea remains one of the few Organization for Economic Cooperation and Development countries without a statutory paid sick leave system or a public sickness benefit program. This paper examines the necessity of introducing statutory paid sick leave in South Korea and outlines key considerations for its implementation. The "right to rest when sick" is a fundamental health and labor right that ensures workers can recover from illness without risking job loss or income insecurity.

View Article and Find Full Text PDF

Purpose: This study investigates factors associated with receiving return-to-work (RTW) coordination within primary healthcare and the association between received RTW coordination and the amount of sickness absence (SA) days.

Methods: This register study included 13019 people who had SA at some time between March 2019 and February 2020 and visited a primary healthcare clinic that employed a RTW coordinator. Logistic regressions were used to investigate received RTW coordination.

View Article and Find Full Text PDF

mediates the sensitivity to irinotecan toxicity via tryptophan catabolites.

Gut

September 2025

Jiangsu Provincial Key Laboratory of Targetome and Innovative Drugs, Institute of Innovative Drug Discovery and Development, China Pharmaceutical University, Nanjing, China

Background: Late-onset diarrhoea remains a poorly managed concern for clinical irinotecan therapy. Although bacterial β-glucuronidases (β-GUS) mediated SN-38 production is prevailingly thought to mediate intestinal toxicity, β-GUS inhibitors confer limited benefits in the clinic.

Objective: This study aimed to explore the role and mechanism of endogenous bacterial metabolites in susceptibility to irinotecan toxicity.

View Article and Find Full Text PDF